CTD²: Cancer Target Discovery and Development

CTD2 bridges the gap between the enormous volumes of data generated by genomic characterization studies and the ability to use these data for the development of human cancer therapeutics. It specializes in computational and functional genomics approaches critical for translating next-generation sequencing data, as well as high-throughput and high content small molecule and genetic screens.

Cancer Target Discovery and Development

News & Publications

previousnext
Cancer Target Discovery and Development Logo
July 18, 2016

NCI's Office of Cancer Genomics has released a new Funding Opportunity Announcement (FOA). This FOA will continue to support the program "Cancer Target Discovery and Development” (CTD^2, pronounced cee-tee-dee-squared).  CTD^2 is focused on efforts that advance cancer research by bridging the...

Human Cancer Models Initiative Banner
July 11, 2016

The NCI Office of Cancer Genomics, along with Cancer Research UK, foundation...

Overview of VIPER method
June 20, 2016

Identifying the multiple dysregulated oncoproteins that contribute to tumorigenesis in a given patient is crucial for developing personalized treatment plans. However, accurate inference of aberrant protein activity in biological samples is still challenging as genetic alterations are only...

genomic data commons graphic
June 06, 2016

The NCI’s Center for Cancer Genomics launches the Genomic Data Commons (GDC), a unified data sharing platform for the cancer research community. The mission of the GDC is to enable data sharing across the entire cancer research community, to ultimately...

May 13, 2016

A new funding opportunity aims to generate novel human tumor-derived culture models that will be made accessible to scientists around the world.

Most cancer cell lines that are commonly used in research labs today were established decades ago and have been propagated in culture for many...

O
O
O
O
O
Last updated: October 21, 2015